Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Pharmacology

Background:

• Community-acquired pneumonia (CAP) is a significant global cause of illness and death.
• Current treatments, including antibiotics, do not fully address CAP's mortality.
• Corticosteroids have shown inconsistent effects on survival in CAP, limiting their use.

Purpose of the Study:

• To investigate the efficacy of corticosteroids in improving clinical outcomes for severe CAP patients with heightened inflammatory responses.
• To determine if corticosteroid use impacts mortality in severe CAP based on disease severity and inflammatory markers.

Main Methods:

• Analysis of two prospective observational cohorts of severe CAP patients in Barcelona and Rome.
• Propensity score (PS) matching to balance baseline characteristics between corticosteroid and non-corticosteroid groups.
• Exclusion of patients with viral pneumonia or those treated with hydrocortisone.

Main Results:

• Corticosteroid therapy was associated with lower 28-day mortality in severe CAP patients meeting major criteria (e.g., septic shock, mechanical ventilation).
• PS-matched analysis showed a significant reduction in 28-day mortality risk with corticosteroids for patients with major severity criteria (HR 0.53).
• No significant mortality benefit was observed in severe CAP patients not meeting major severity criteria.

Conclusions:

• Corticosteroid treatment appears beneficial for severe CAP patients experiencing septic shock and/or requiring invasive mechanical ventilation.
• The use of corticosteroids did not demonstrate a mortality benefit in severe CAP patients without these critical features.